Concert Pharma (CNCE) Tops Q2 EPS by 28c

Go back to Concert Pharma (CNCE) Tops Q2 EPS by 28c

Concert Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Company Update

August 6, 2020 7:00 AM EDT

CTP-543 Phase 3 Trial Initiation in Alopecia Areata Expected to Begin Fourth Quarter 2020

CTP-692 Phase 2 Trial Enrollment in Schizophrenia Expected to be Complete by Year-End 2020

Conference Call Scheduled Today at 8:30 a.m. ET

LEXINGTON, Mass.--(BUSINESS WIRE)--... More